| Metric | Value ($ M) |
|---|---|
| Revenue | 0.36 |
| Total Income | 0.36 |
| Expenditure | 21.27 |
| PBT | — |
| Net Profit | -19.91 |
| OPM | — |
| NPM | — |
| EPS | -2.08 |
Seres Therapeutics Reports Q1 2026 Financial Results
05 May 2026 · 5 May, 4:38 pm
Summary
Seres Therapeutics reported first quarter 2026 financial results, with a net loss of $19.9 million compared to a net income of $32.7 million in the same period of 2025. The prior year's net income included a $50 million payment from Nestlé. Research and development expenses increased to $13.2 million, while general and administrative expenses decreased to $8.1 million. The company's cash and cash equivalents totaled $29.8 million as of March 31, 2026, and it expects to fund operations through the third quarter of 2026.
Key Highlights
- 1
Seres Therapeutics reported a net loss of $19.9 million for the first quarter of 2026, compared to a net income of $32.7 million for the same period in 2025.
- 2
The first quarter of 2025 included a $50 million installment payment from Nestlé related to transition services following the sale of VOWST.
- 3
Research and development expenses were $13.2 million for the first quarter of 2026, compared with $11.8 million for the same period in 2025.
- 4
General and administrative expenses were $8.1 million for the first quarter of 2026, compared with $11.9 million for the same period in 2025.
- 5
As of March 31, 2026, Seres had $29.8 million in cash and cash equivalents.
- 6
The company expects to fund operations through the third quarter of 2026 based on its current cash position and operating plans.
- 7
Clinical readout from investigator-sponsored SER-155 study in immune checkpoint inhibitor-related enterocolitis is expected in the coming weeks.
Management Comments
Richard Kender
“We are approaching an important clinical milestone with the expected readout in the coming weeks from the investigator-sponsored study at Memorial Sloan Kettering Cancer Center, an institution with whom we’ve collaborated for over a decade, evaluating SER-155 in immune checkpoint inhibitor-related enterocolitis (irEC). irEC is a serious condition which represents a meaningful therapeutic and commercial opportunity, and with positive data we will evaluate potential development pathways and adjacent expansion opportunities. In parallel, we are advancing our inflammatory and immunology portfolio, including SER-603 for inflammatory bowel disease, with IND-enabling work progressing. We have achieved Phase 2 readiness for SER-155 for the prevention of bloodstream infections in patients undergoing allo-HSCT for the treatment of blood cancer and are seeking funding to commence the study. We are continuing disciplined capital allocation while actively pursuing partnerships and other financing sources to support Seres’ pipeline advancement and long-term value creation.”
Informational and educational content only. Not investment advice.